ATE298245T1 - Verwendung von equiner-herpes-virus-typ-4- thymidin-kinase und einen nucleosidanalog ausgewählt von ganciclovir und acyclovir zur tötung von proliferativen humanzellen - Google Patents

Verwendung von equiner-herpes-virus-typ-4- thymidin-kinase und einen nucleosidanalog ausgewählt von ganciclovir und acyclovir zur tötung von proliferativen humanzellen

Info

Publication number: ATE298245T1
Authority: AT; Austria
Prior art keywords: thymidine kinase; virus type; herpes virus; human cells; nucleoside
Prior art date: 1999-04-20

Application number

AT99400964T

Other languages

English (en)

Inventor

David Klatzmann

Laurence Loubiere

Original Assignee

Univ Paris Curie

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-04-20

Filing date

1999-04-20

Publication date

2005-07-15

1999-04-20 Application filed by Univ Paris Curie filed Critical Univ Paris Curie

2005-07-15 Application granted granted Critical

2005-07-15 Publication of ATE298245T1 publication Critical patent/ATE298245T1/de

Links

241000701089 Equid alphaherpesvirus 4 Species 0.000 title abstract 3
102000006601 Thymidine Kinase Human genes 0.000 title abstract 3
108020004440 Thymidine kinase Proteins 0.000 title abstract 3
210000005260 human cell Anatomy 0.000 title abstract 3
239000002777 nucleoside Substances 0.000 title abstract 3
150000003833 nucleoside derivatives Chemical class 0.000 title abstract 3
230000002062 proliferating effect Effects 0.000 title abstract 2
229960004150 aciclovir Drugs 0.000 title 1
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 title 1
229960002963 ganciclovir Drugs 0.000 title 1
IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 title 1
150000007523 nucleic acids Chemical class 0.000 abstract 2
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 abstract 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 abstract 1
230000001028 anti-proliverative effect Effects 0.000 abstract 1
230000000259 anti-tumor effect Effects 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
238000000338 in vitro Methods 0.000 abstract 1
238000001727 in vivo Methods 0.000 abstract 1
230000010534 mechanism of action Effects 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
102000039446 nucleic acids Human genes 0.000 abstract 1
108020004707 nucleic acids Proteins 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
229920001184 polypeptide Polymers 0.000 abstract 1
102000004196 processed proteins & peptides Human genes 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
238000009877 rendering Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Gastroenterology & Hepatology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Enzymes And Modification Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AT99400964T 1999-04-20 1999-04-20 Verwendung von equiner-herpes-virus-typ-4- thymidin-kinase und einen nucleosidanalog ausgewählt von ganciclovir und acyclovir zur tötung von proliferativen humanzellen ATE298245T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP99400964A EP1046400B1 (de)	1999-04-20	1999-04-20	Verwendung von equiner-Herpes-Virus-typ-4-Thymidin-Kinase und einen Nucleosidanalog ausgewählt von Ganciclovir und Acyclovir zur Tötung von proliferativen Humanzellen

Publications (1)

Publication Number	Publication Date
ATE298245T1 true ATE298245T1 (de)	2005-07-15

Family

ID=8241950

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99400964T ATE298245T1 (de)	1999-04-20	1999-04-20	Verwendung von equiner-herpes-virus-typ-4- thymidin-kinase und einen nucleosidanalog ausgewählt von ganciclovir und acyclovir zur tötung von proliferativen humanzellen

Country Status (5)

Country	Link
EP (1)	EP1046400B1 (de)
JP (1)	JP2001031587A (de)
AT (1)	ATE298245T1 (de)
CA (1)	CA2306355A1 (de)
DE (1)	DE69925894T2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5757608B2 (ja) *	2009-11-18	2015-07-29	国立大学法人千葉大学	遺伝子スイッチおよび遺伝子回路の選択方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9014951D0 (en) *	1990-07-06	1990-08-29	Univ Glasgow	Equine herpesvirus-4 tk vaccine
FR2716459B1 (fr) *	1994-02-22	1996-05-10	Univ Paris Curie	Système hôte-vecteur utilisable en thérapie génique.

1999
- 1999-04-20 AT AT99400964T patent/ATE298245T1/de not_active IP Right Cessation
- 1999-04-20 EP EP99400964A patent/EP1046400B1/de not_active Expired - Lifetime
- 1999-04-20 DE DE69925894T patent/DE69925894T2/de not_active Expired - Lifetime
2000
- 2000-04-19 CA CA002306355A patent/CA2306355A1/en not_active Abandoned
- 2000-04-20 JP JP2000159149A patent/JP2001031587A/ja active Pending

Also Published As

Publication number	Publication date
DE69925894D1 (de)	2005-07-28
JP2001031587A (ja)	2001-02-06
DE69925894T2 (de)	2006-05-11
EP1046400A1 (de)	2000-10-25
EP1046400B1 (de)	2005-06-22
CA2306355A1 (en)	2000-10-20

Similar Documents

Publication	Publication Date	Title
Franceschi et al.	2000	Gene therapy for bone formation: in vitro and in vivo osteogenic activity of an adenovirus expressing BMP7
Garmyn et al.	1992	Effect of aging and habitual sun exposure on the genetic response of cultured human keratinocytes to solar-simulated irradiation
DE69230993D1 (de)	2000-06-08	Rekombinante viren vektoren zur expression in muskelzellen
ATE190354T1 (de)	2000-03-15	Kontrolle der genexpression durch ionisierende strahlung
WO2000006705A3 (de)	2000-05-04	Genetisch modifizierte cd34-negative, adhärent wachsende stammzellen und deren verwendung in der gentherapie
Pferdehirt et al.	2019	A synthetic gene circuit for self-regulating delivery of biologic drugs in engineered tissues
BR9914643A (pt)	2001-12-11	Vetores adeno-associados para expressão dofator viii por células alvo
DK478786A (da)	1986-12-08	Cystein-forarmede muteiner af biologisk aktive humantumornekrosefaktorproteiner
ES2183811T3 (es)	2003-04-01	Tratamiento de enfermedades tumorigenas con un hsv modificado.
Nilsen-Hamilton et al.	1981	Stimulation of the release of two glycoproteins from mouse 3T3 cells by growth factors and by agents that increase intralysosomal pH
SE9002589D0 (sv)	1990-08-07	Neutrofil-aktiverande peptid-2
ATE430763T1 (de)	2009-05-15	Therapeutische verwendung des wachstumsfaktors nsg33
Meek	1997	Post-translational modification of p53 and the integration of stress signals
ATE291619T1 (de)	2005-04-15	Dap-2 tumorsupressorgen, durch sie kodierte protein und verwendung besagter gen und protein
Kaplitt et al.	1995	Viral vectors: gene therapy and neuroscience applications
DK1373502T3 (da)	2011-01-10	Dopaminerge neuronale overlevelsesfremmende faktorer og avendelser heraf
DE69832989D1 (de)	2006-02-02	Genetisch manipulierte zellen die knochenmorphogeneseproteinen exprimieren
ATE298245T1 (de)	2005-07-15	Verwendung von equiner-herpes-virus-typ-4- thymidin-kinase und einen nucleosidanalog ausgewählt von ganciclovir und acyclovir zur tötung von proliferativen humanzellen
ATE310828T1 (de)	2005-12-15	Implantat und vektor zur behandlung von erworbenen krankheiten
Takeshita et al.	1992	Effect of interleukin‐1β on gene expressions and functions of fibroblastic cells derived from human periodontal ligament
Singh et al.	2021	Tissue engineering: the biologic modifiers in periodontal regeneration
ATE317905T1 (de)	2006-03-15	Arzneimittel enthaltend wenigstens einen teil des ul84-proteins des cytomegalovirus, verwendung von polypeptiden entsprechend der aminosäuresequenz des ul84-proteins und verfahren zur einführung von ul84 in zielzellen
Green et al.	1989	Quantitative comparison of mesoderm inducing factors in xenopus
DE59909197D1 (de)	2004-05-19	Verfahren zur auslösung von apoptose in zellen
Wright et al.	2002	EX VIVO GENE THERAPY BASED ON HUMAN WHITE BLOOD CELLS (WBC) INDUCE BONE GROWTH IN VIVO

Legal Events

Date	Code	Title	Description
2005-12-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties